Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study

Y Huo, Z C Jing, X F Zeng, J M Liu, Z X Yu, G C Zhang, Y Li, Y Wang, Q S Ji, P Zhu, B X Wu, Y Zheng, P P Wang, J Li, Y Huo, Z C Jing, X F Zeng, J M Liu, Z X Yu, G C Zhang, Y Li, Y Wang, Q S Ji, P Zhu, B X Wu, Y Zheng, P P Wang, J Li

Abstract

Background: Although several new drugs have been approved in recent years, pulmonary arterial hypertension (PAH) remains a rapidly progressive disease with a poor prognosis. Ambrisentan, a selective endothelin type A antagonist, has been approved for treatment of PAH. This open label study assessed the efficacy and safety of ambrisentan in Chinese subjects with PAH.

Methods: Eligible patients with PAH (World Health Organisation [WHO] functional class [FC] II orIII) were enrolled and received Ambrisentan (5 mg) once daily for a 12-week preliminary evaluation period, and a 12-week dose-adjustment period (dose titration to 10 mgallowed). Endpoints included: change from baseline in 6-Minute Walk Distance (6-MWD), N-Terminal Pro B-Type Natriuretic Peptide (NT-pro-BNP), WHO FC, Borg Dyspnoea Index (BDI), clinical worsening of PAH and incidences of adverse events (AE).

Results: One hundred thirty-three subjects (85 % women, mean age: 36 years) with PAH (WHOFC II or III) were enrolled and received ambrisentan (5 mg) once daily for a 12-week preliminary evaluation period, and a 12-week dose-adjustment period. Mean (SD) duration of drug exposure was 161.7 (27.13) days. Ambrisentan (average daily dose of 6.27 mg) significantly improved exercise capacity (6MWD) from baseline (mean: 377.1 m [m]) at week 12 (+53.6 m, p < 0.001) (primary endpoint). Improvement in exercise capacity was noted as early as week 4, and was sustained up to week 24 (+ 64.4 m, p < 0.001). NT-pro-BNP plasma levels decreased significantly (p < 0.001) at week 12 (-861.4 ng/L) and week 24 (-806 ng/L) from baseline (mean: 1600.7 ng/L). The WHO FC showed improvements for 44 subjects at week 12 and 51 subjects at week 24. BDI scores decreased significantly at week 12 (-0.3, p < 0.001) and week 24 (-0.2, p = 0.003) from baseline (mean: 2.5). Four patients died during the study (sudden cardiac death [n = 2], cerebral haemorrhage [n = 1], cardiac failure [n = 1]). Drug related adverse events occurred in 34.3 % of subjects; peripheral oedema (11.2 %) and flushing (8.2 %) occurred most frequently.

Conclusion: Ambrisentan (5 and 10 mg, orally) significantly improved the exercise capacity in Chinese PAH subjects with a safety profile similar to that observed in global studies.

Trial registration: NCT No. (ClinicalTrials.gov): NCT01808313 ; Registration date (first time): February 28, 2013.

Keywords: Ambrisentan; Chinese; Exercise capacity; Pulmonary arterial hypertension.

Figures

Fig. 1
Fig. 1
Improvement in 6MWD over 24 weeks following ambrisentan treatment (LOCF) (ITT population). Note: Mean (SD) baseline value for 6MWD was 377.1 (61.30) meters. AMB: ambrisentan
Fig. 2
Fig. 2
Kaplan-Meier plot for time to clinical worsening (safety population)

References

    1. Galiè N, Hoeper M, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219–63. doi: 10.1183/09031936.00139009.
    1. Baldi F, Fuso L, Arrighi E, Valente S. Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. Ther Clin Risk Manag. 2014;10:825–39.
    1. Mandras SA, Gilkin RJ, Pruett JA. Pulmonary arterial hypertension: progress and challenges in the modern treatment era. Am J Manag Care. 2014;20(9 Suppl):S191–9.
    1. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780–8. doi: 10.1016/S0735-1097(02)02012-0.
    1. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477–82. doi: 10.1161/01.CIR.0000029100.82385.58.
    1. Elshaboury SM, Anderson JR. Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes. Patient Prefer Adherence. 2013;7:401–9.
    1. Galiè N, Horst O, Ronald J, Fernando Torres O, Adaani F, Hossein A, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation. 2008;117:3010–9. doi: 10.1161/CIRCULATIONAHA.107.742510.
    1. Oudiz R, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ, ARIES Study Group Long-term Ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(21):1971–81. doi: 10.1016/j.jacc.2009.07.033.
    1. LETAIRIS® prescribing information, revised on 2015 .
    1. Burroughs VJ, Maxey RW, et al. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94(10 Suppl):1–26.
    1. ATS Statement Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7. doi: 10.1164/ajrccm.166.1.at1102.
    1. Jing Z. 2006 Six minute walk test in clinical practice Chin J Cardiol. 2006;34(4):183–187.
    1. Bosworth. Perspectives on Pulmonary Arterial Hypertension (PAH) - Reviews from published literature. 2014. (viewed on 2 January 2015).
    1. Valerio CJ, Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag. 2009;5:607–19. doi: 10.2147/VHRM.S4713.
    1. Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, Steedman T, Morton JJ, Dargie HJ, Peacock AJ. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J. 2007;29(4):737–44. doi: 10.1183/09031936.00095606.
    1. Vachiéry J-L, Yerly P, Huez S. How to detect disease progression in pulmonary arterial hypertension. Eur Respir Rev. 2012;21(123):40–7. doi: 10.1183/09059180.00009011.
    1. Ramos RP, Arakaki JS, Barbosa P, Treptow E, Valois FM, Ferreira EV, Nery LE, Neder JA. Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. Am Heart J. 2012;163:580–9. doi: 10.1016/j.ahj.2012.01.023.
    1. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529–35. doi: 10.1016/j.jacc.2005.04.050.
    1. Yoshida S, Shirato K, Shimamura R, Nakahara N, Iwase T, Nakajima H. Efficacy, safety, and pharmacokinetics of Ambrisentan in Japanese adults with pulmonary arterial hypertension. Curr Med Res Opin. 2011;27(9):1827–34. doi: 10.1185/03007995.2011.605440.
    1. Yoshida S, Shirato K, Shimamura R, Iwase T, Aoyagi N, Nakajima H. Long-term safety and efficacy of Ambrisentan in Japanese adults with pulmonary arterial hypertension. Curr Med Res Opin. 2012;28(6):1069–76. doi: 10.1185/03007995.2012.685930.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit